Leukemia Research
Volume 27, Issue 6 , Pages 499-504 , June 2003

Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia

  • Jung M. Chou

      Affiliations

    • Division of Hematopathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
    • ,
  • Chin-Yang Li

      Affiliations

    • Division of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • ,
  • Ayalew Tefferi

      Affiliations

    • Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author.

Received 5 August 2002 ,Revised 7 October 2002 ,Accepted 11 October 2002.

References 

  1. Tefferi A. Myelofibrosis with myeloid metaplasia. New Engl. J. Med. 2000;342:1255–1265
  2. Hasselbalch H. Idiopathic myelofibrosis: a review. Eur. J. Haematol. 1990;45:65–72
  3. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, et al.  Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br. J. Haematol. 1997;97:441–448
  4. Le Bousse-Kerdiles MC, Martyre MC. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol. Biol. Paris. 2001;49:153–157
  5. Dalley A, Smith JM, Reilly JT, Neil SM. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br. J. Haematol. 1996;93:856–862
  6. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 1994;91:4082–4085
  7. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann. Hematol. 1999;78:437–444
  8. Beck L, D’Amore PA. Vascular development: cellular and molecular regulation. FASEB J. 1997;11:365–373
  9. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233–242
  10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  11. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 1995;121:1845–1854
  12. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96:2022–2036
  13. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schultz P, Heldin CH, et al.  Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 1993;75:681–692
  14. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992;68:775–785
  15. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Chevillard S, Benyahia B, et al.  Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br. J. Haematol. 1994;88:9–16
  16. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J. Clin. Invest. 1990;85:916–920
  17. Kimura A, Katoh O, Kuramoto A. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br. J. Haematol. 1988;69:9–12
  18. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin. Haematol. 1998;11:751–767
  19. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991;5:1806–1814
  20. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al.  The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991;18:11947–11954
  21. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999;9:211–220
  22. Coulier F, Pontarotti P, Roubin R, Hartung H, Goldfarb M, Birnbaum D. Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J. Mol. Evol. 1997;44:43–56
  23. Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SH, Gilbert DJ, et al.  Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc. Natl. Acad. Sci. U.S.A. 1996;93:9850–9857
  24. Hoshikawa M, Ohbayashi N, Yonamine A, Konishi M, Ozaki K, Fukui S, et al.  Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain. Biochem. Biophys. Res. Commun. 1998;244:187–191
  25. Ohbayashi N, Hoshikawa M, Kimura S, Yamasaki M, Fukui S, Itoh N. Structure and expression of the mRNA encoding a novel fibroblast growth factor, FGF-18. J. Biol. Chem. 1998;273:18161–18164
  26. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 2000;104:151–157
  27. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 1999;106:682–688
  28. Yoon SY, Tefferi A, Li CY. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders. Haematologica. 2001;86:52–57
  29. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374–3380
  30. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 1995;9:919–925
  31. Amizuka N, Yamada M, Watanabe JI, Hoshi K, Fukushi M, Oda K, et al.  Morphological examination of bone synthesis via direct administration of basic fibroblast growth factor into rat bone marrow. Microsc. Res. Tech. 1998;41:313–322
  32. Chen QS, Wang ZY, Han ZC. Enhanced growth of megakaryocyte colonies in culture in the presence of heparin and fibroblast growth factor. Int. J. Hematol. 1999;70:155–162
  33. Faloon P, Arentson E, Kazarov A, Deng CX, Porcher C, Orkin S, et al.  Basic fibroblast growth factor positively regulates hematopoietic development. Development. 2000;127:1931–1941
  34. Padgett RW, Das P, Krishna S. TGF-beta signaling, Smads, and tumor suppressors. Bioessays. 1998;20:382–390
  35. Ren P, Lim CS, Johnsen R, Albert PS, Pilgrim D, Riddle DL. Control of C. elegans larval development by neuronal expression of a TGF-beta homolog. Science. 1996;274:1389–1391
  36. Colavita A, Krishna S, Zheng H, Padgett RW, Culotti JG. Pioneer axon guidance by UNC-129, a C. elegans TGF-beta. Science. 1998;281:706–709
  37. Suzuki Y, Yandell MD, Roy PJ, Krishna S, Savage-Dunn C, Ross RM, et al.  A BMP homolog acts as a dose-dependent regulator of body size and male tail patterning in Caenorhabditis elegans. Development. 1999;126:241–250
  38. Morita K, Chow KL, Ueno N. Regulation of body length and male tail ray pattern formation of Caenorhabditis elegans by a member of TGF-beta family. Development. 1999;126:1337–1347
  39. Marques G, Musacchio M, Shimell MJ, Wunnenberg-Stapleton K, Cho KW, O’Connor MB. Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins. Cell. 1997;91:417–426
  40. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al.  Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2000;97:2626–2631
  41. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type 1 receptor-deficient mice. EMBO J. 2001;20:1663–1673
  42. Goumans MJ, Mummery C. Functional analysis of the TGF-beta receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 2000;44:253–265
  43. Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, et al.  Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2002;117:288–296
  44. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99:2252–2254
  45. Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncey T, Appelbaum FR, et al.  Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586–593

PII: S0145-2126(02)00268-0

doi: 10.1016/S0145-2126(02)00268-0

Leukemia Research
Volume 27, Issue 6 , Pages 499-504 , June 2003

Article Tools

* Image Usage & Resolution